CA15.3 Serum Concentrations in Older Women with Infiltrating Ductal Carcinomas of the Breast
Abstract
:1. Introduction
2. Results and Discussion
Number of Patients | Median (Range) | p-Value | ||||
---|---|---|---|---|---|---|
Parameter | >70 years | <70 years | >70 years | <70 years | >70 years | <70 years |
N− | 40 | 136 | 21 (6–45) | 17 (1–57) | ns | 0.006 |
N+ | 29 | 69 | 23 (7–54) | 23 (6–191) | ||
M− | 54 | 191 | 22 (6–55) | 18 (4–162) | ns | 0.001 |
M+ | 15 | 14 | 25 (10–86) | 32 (11–17,340) | ||
HGI | 9 | 38 | 24 (11–32) | 16 (8–17,340) | ns | 0.085 |
HGIII | 23 | 64 | 20 (10–55) | 20 (4–191) | ||
≤2 cm | 35 | 142 | 20 (6–42) | 18 (1–57) | 0.041 | 0.014 |
>2 cm | 34 | 63 | 25 (7–86) | 23 (8–17,340) |
>23 | ≤23 | p-Value | |
---|---|---|---|
Parameter | Median (Range) | Median (Range) | |
Size | 2.5 (0.7–8) | 2.0 (0.9–9) | 0.018 |
Number of Patients | Number of Patients | ||
>2 cm | 20/32 (63%) | 14/37 (38%) | 0.041 |
N+ | 14/32 (44%) | 16/37 (43%) | ns |
N + 3 | 7/32 (22%) | 12/37(32%) | ns |
M+ | 8/32 (25%) | 7/37 (19%) | ns |
HGIII | 9/32 (29%) | 14/37 (38%) | ns |
3. Experimental Section
3.1. Study Design
3.2. Subjects
3.3. Blood Samples and Methods
3.4. Statistics Analysis
4. Conclusions
Acknowledgments
Author Contributions
Conflicts of Interest
References
- Duffy, M.J.; Evoy, D.; McDermott, E.W. CA 15.3: Uses and limitation as a biomarker for breast cancer. Clin. Chim. Acta 2010, 14, 1869–1874. [Google Scholar]
- Wu, S.G.; He, Z.Y.; Zhou, J.; Son, J.Y.; Li, F.Y.; Lin, Q. Serum levels of CEA and CA15.3 in different molecular subtypes and prognostic value in chinese breast cancer. Breast 2014, 23, 88–93. [Google Scholar]
- Di Goia, D.; Heinemann, V.; Nagel, D.; Untch, N.; Kahlert, S.; Bauerfeind, I. Kinetics of CEA and CA 15.3 correlate with treatment response in patients undergoing chemotherapy for metastatic breast cancer (MBC). Tumor Biol. 2011, 32, 777–785. [Google Scholar]
- Incoronato, M.; Mirabelli, P.; Catalano, O.; Ajello, M.; Parente, C.; Soricelli, A. CA 15.3 is a useful serum tumor marker for diagnostic integration of hybrid positron emission tomography with integrated computed tomography during follow-up of breast cancer patients. BMC Cancer 2014, 14. [Google Scholar] [CrossRef]
- Nath, S.; Mukherjee, P. MUC1: A multifaceted oncoprotein with a key role in cancer progression. Tends Mol. Med. 2014, 20, 332–342. [Google Scholar]
- Alvarado, R.; Lari, S.A.; Roses, R.E.; Smith, B.D.; Yang, W.; Mittendorf, E.A. Biology, treatment, and outcome in very young and older women with DCIS. Ann. Surg. Oncol. 2012, 19, 3777–3784. [Google Scholar]
- Sennerstam, R.B.; Wiksell, H.; Schässburger, K.U.; Auer, G.U. Breast cancer and clinical outcome among women over 60 years of age: A plead for more screening and alternative treatments. Anal. Q. Cytol. Histol. 2012, 34, 189–194. [Google Scholar]
- Tea, M.K.; Tang, L.; Di, G.H.; Muin, D.; Steurer, S.; Delancey, J.W. A cross-sectional study of elderly Asian and European women with primary operable breast cancer aged 70 and older. Are there differences? Maturitas 2012, 73, 251–254. [Google Scholar]
- Dialla, P.O.; Dabakuyo, T.S.; Marilier, S.; Gentil, J.; Roignot, P.; Darut-Jouve, A. Population-based study of breast cancer in older women: Prognostic factors of relative survival and predictors of treatment. BMC Cancer 2012, 12. [Google Scholar] [CrossRef]
- Alvaro-Meca, A.; Debón, A.; Gil Prieto, R.; Gil de Miguel, A. Breast cancer mortality in Spain: Has a really declined for all age groups? Public Health 2012, 126, 891–895. [Google Scholar]
- Colomer, R.; Ruibal, A.; Salvador, L. Circulating tumor marker levels in advanced breast carcinoma correlate with the extent of metastatic disease. Cancer 1989, 64, 1674–1681. [Google Scholar]
- Colomer, R.; Ruibal, A.; Navarro, M.; Encabo, G.; Sole, L.A.; Salvador, L. Serum CA 15.3 levels in patients with non-tumoral diseases, and establishment of a threshold for tumoral activity. Results in 1219 patients. Int. J. Biol. Markers 1986, 1, 159–160. [Google Scholar]
- Lee, J.S.; Park, S.; Park, J.M.; Cho, J.H.; Kim, S.I.; Park, B.W. Elevated levels of preoperative CA 15.3 and CEA serum concentrations have independently poor prognostic significance in breast cancer. Ann. Oncol. 2013, 24, 1225–1231. [Google Scholar]
- Sandri, M.T.; Salvatici, M.; Botteri, E.; Passerini, R.; Zorzino, L.; Rotmensz, N. Prognostic role of CA 15.3 in 7942 patients with operable breast cancer. Breast Cancer Res. Treat. 2012, 132, 317–326. [Google Scholar]
- Hashim, Z.M. The significance of CA15.3 in breast cancer patients and its relationship to HER2 receptor status. Int. J. Immunopathol. Pharmacol. 2014, 27, 45–51. [Google Scholar]
- Ruibal, A.; Sánchez Salmon, A.; Garrido, M.; Ciobotaru, A.B.; Arias, J.I. Preoperative CA 15.3 serum levels and cellular proliferation in patients with infiltrating ductal carcinomas of the breast. Rev. Esp. Med. Nucl. 2007, 26, 367–371. [Google Scholar]
- Gonzalez Sistal, A.; Arias, J.I.; Ruibal, A. CA 15.3 concentrations in patients with ductal breast carcinoma: Relationship with clinicopathological parameters and tumor markers. Int. J. Biol. Markers 2012, 27, 47–52. [Google Scholar]
- Lumachi, F.; Basso, S.M.; Bonamini, M.; Marzano, B.; Milan, E.; Waclaw, B.U. Relationship between preoperative serum markers CA 15.3 and CEA and relapse of the disease in elderly (>65 years) women with breast cancer. Anticancer Res. 2010, 30, 2331–2334. [Google Scholar]
- Ruibal, A.; Sánchez Salmón, A. Reduced clinicopathological influence of hormone-dependence on breast carcinomas in women older than 70 years. Int. J. Biol. Markers 2008, 23, 58–62. [Google Scholar]
© 2014 by the authors; licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution license (http://creativecommons.org/licenses/by/4.0/).
Share and Cite
Ruibal, Á.; Aguiar, P.; Del Río, M.C.; Padín-Iruegas, M.E.; Arias, J.I.; Herranz, M. CA15.3 Serum Concentrations in Older Women with Infiltrating Ductal Carcinomas of the Breast. Int. J. Mol. Sci. 2014, 15, 19870-19876. https://doi.org/10.3390/ijms151119870
Ruibal Á, Aguiar P, Del Río MC, Padín-Iruegas ME, Arias JI, Herranz M. CA15.3 Serum Concentrations in Older Women with Infiltrating Ductal Carcinomas of the Breast. International Journal of Molecular Sciences. 2014; 15(11):19870-19876. https://doi.org/10.3390/ijms151119870
Chicago/Turabian StyleRuibal, Álvaro, Pablo Aguiar, María Carmen Del Río, María Elena Padín-Iruegas, José Ignacio Arias, and Michel Herranz. 2014. "CA15.3 Serum Concentrations in Older Women with Infiltrating Ductal Carcinomas of the Breast" International Journal of Molecular Sciences 15, no. 11: 19870-19876. https://doi.org/10.3390/ijms151119870